Literature DB >> 26180080

Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Veronica R Placencio1, Yves A DeClerck2.   

Abstract

Despite its function as an inhibitor of urokinase and tissue-type plasminogen activator (PA), PA inhibitor-1 (PAI-1) has a paradoxical protumorigenic role in cancer, promoting angiogenesis and tumor cell survival. In this review, we summarize preclinical evidence in support of the protumorigenic function of PAI-1 that has led to the testing of small-molecule PAI-1 inhibitors, initially developed as antithrombotic agents, in animal models of cancer. The review discusses the challenges and the opportunities that lay ahead to the development of efficacious and nontoxic PAI-1 inhibitors as anticancer agents. ©2015 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26180080      PMCID： PMC4613764          DOI： 10.1158/0008-5472.CAN-15-0876

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  58 in total

1.  SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis.

Authors:  Takeshi Masuda; Noboru Hattori; Tadashi Senoo; Shin Akita; Nobuhisa Ishikawa; Kazunori Fujitaka; Yoshinori Haruta; Hiroshi Murai; Nobuoki Kohno
Journal:  Mol Cancer Ther       Date:  2013-08-29       Impact factor: 6.261

2.  Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer.

Authors:  Satsuki Mashiko; Kazuyuki Kitatani; Masafumi Toyoshima; Atsuhiko Ichimura; Takashi Dan; Toshinori Usui; Masumi Ishibashi; Shogo Shigeta; Satoru Nagase; Toshio Miyata; Nobuo Yaegashi
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

3.  Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model.

Authors:  Evan Gomes-Giacoia; Makito Miyake; Steve Goodison; Charles J Rosser
Journal:  Mol Cancer Ther       Date:  2013-09-26       Impact factor: 6.261

4.  Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.

Authors:  Veronica R Placencio; Atsuhiko Ichimura; Toshio Miyata; Yves A DeClerck
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

Review 5.  Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview.

Authors:  Anne Rouch; Corinne Vanucci-Bacqué; Florence Bedos-Belval; Michel Baltas
Journal:  Eur J Med Chem       Date:  2015-01-08       Impact factor: 6.514

6.  Serpins promote cancer cell survival and vascular co-option in brain metastasis.

Authors:  Manuel Valiente; Anna C Obenauf; Xin Jin; Qing Chen; Xiang H-F Zhang; Derek J Lee; Jamie E Chaft; Mark G Kris; Jason T Huse; Edi Brogi; Joan Massagué
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

Review 7.  Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present).

Authors:  Yolanda M Fortenberry
Journal:  Expert Opin Ther Pat       Date:  2013-03-25       Impact factor: 6.674

8.  Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1.

Authors:  Shih-Hon Li; Ashley A Reinke; Karen L Sanders; Cory D Emal; James C Whisstock; Jeanne A Stuckey; Daniel A Lawrence
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

9.  Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function.

Authors:  Hua Fang; Veronica R Placencio; Yves A DeClerck
Journal:  J Natl Cancer Inst       Date:  2012-09-13       Impact factor: 13.506

10.  Activators and inhibitors of the plasminogen system in Alzheimer's disease.

Authors:  Rachel Barker; Patrick G Kehoe; Seth Love
Journal:  J Cell Mol Med       Date:  2012-04       Impact factor: 5.310
View more
  60 in total

1.  Dual-reporter high-throughput screen for small-molecule in vivo inhibitors of plasminogen activator inhibitor type-1 yields a clinical lead candidate.

Authors:  Ashley A Reinke; Shih-Hon Li; Mark Warnock; Maxim E Shaydakov; Naga Sandhya Guntaka; Enming J Su; Jose A Diaz; Cory D Emal; Daniel A Lawrence
Journal:  J Biol Chem       Date:  2018-12-03       Impact factor: 5.157

2.  Transcriptomic Analysis of Cellular Pathways in Healing Flexor Tendons of Plasminogen Activator Inhibitor 1 (PAI-1/Serpine1) Null Mice.

Authors:  Margaret A T Freeberg; Anas Easa; Jacquelyn A Lillis; Danielle S W Benoit; Andre J van Wijnen; Hani A Awad
Journal:  J Orthop Res       Date:  2019-09-01       Impact factor: 3.494

3.  Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer.

Authors:  Brock A Humphries; Johanna M Buschhaus; Yu-Chih Chen; Henry R Haley; Tonela Qyli; Benjamin Chiang; Nathan Shen; Shrila Rajendran; Alyssa Cutter; Yu-Heng Cheng; Yu-Ting Chen; Jason Cong; Phillip C Spinosa; Euisik Yoon; Kathryn E Luker; Gary D Luker
Journal:  Mol Cancer Res       Date:  2019-02-04       Impact factor: 5.852

4.  Plasminogen Activator Inhibitor-1 Promotes the Recruitment and Polarization of Macrophages in Cancer.

Authors:  Marta Helena Kubala; Vasu Punj; Veronica Rae Placencio-Hickok; Hua Fang; G Esteban Fernandez; Richard Sposto; Yves Albert DeClerck
Journal:  Cell Rep       Date:  2018-11-20       Impact factor: 9.423

5.  Single-cell transcriptional changes associated with drug tolerance and response to combination therapies in cancer.

Authors:  Alexandre F Aissa; Abul B M M K Islam; Majd M Ariss; Cammille C Go; Alexandra E Rader; Ryan D Conrardy; Alexa M Gajda; Carlota Rubio-Perez; Klara Valyi-Nagy; Mary Pasquinelli; Lawrence E Feldman; Stefan J Green; Nuria Lopez-Bigas; Maxim V Frolov; Elizaveta V Benevolenskaya
Journal:  Nat Commun       Date:  2021-03-12       Impact factor: 14.919

Review 6.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

7.  Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.

Authors:  Veronica R Placencio; Atsuhiko Ichimura; Toshio Miyata; Yves A DeClerck
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

8.  Diabetes-associated dysregulated cytokines and cancer.

Authors:  Yong Wu; Yanjun Liu; Yunzhou Dong; Jay Vadgama
Journal:  Integr Cancer Sci Ther       Date:  2016-02-15

9.  Molecular mechanism of two nanobodies that inhibit PAI-1 activity reveals a modulation at distinct stages of the PAI-1/plasminogen activator interaction.

Authors:  Machteld Sillen; Stephen D Weeks; Xiaohua Zhou; Andrey A Komissarov; Galina Florova; Steven Idell; Sergei V Strelkov; Paul J Declerck
Journal:  J Thromb Haemost       Date:  2020-02-20       Impact factor: 5.824

10.  Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1.

Authors:  James V McCann; Lin Xiao; Dae Joong Kim; Omar F Khan; Piotr S Kowalski; Daniel G Anderson; Chad V Pecot; Salma H Azam; Joel S Parker; Yihsuan S Tsai; Alisa S Wolberg; Stephen D Turner; Kohei Tatsumi; Nigel Mackman; Andrew C Dudley
Journal:  J Clin Invest       Date:  2019-03-11       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.